Breaking News
Get 55% Off 0
🏃 Grab this Black Friday offer early. Get up to 55% off InvestingPro now!
CLAIM SALE
Close

Franklin Biotechnology Discovery Fund N(acc)usd (0P00000MJJ)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
36.570 -1.080    -2.87%
12/11 - Closed. Currency in USD
Type:  Fund
Market:  Luxembourg
ISIN:  LU0122613499 
Asset Class:  Equity
  • Morningstar Rating:
  • Total Assets: 113.81M
Franklin Biotechnology Discovery Fund N(acc)USD 36.570 -1.080 -2.87%

0P00000MJJ Overview

 
On this page you'll find an in-depth profile of Franklin Biotechnology Discovery Fund N(acc)usd. Learn about the key management, total assets, investment strategy and contact information of 0P00000MJJ among other information.
Category

Sector Equity Biotechnology

Total Assets

113.81M

Expenses

2.57%

Inception Date

Dec 29, 2000

Contact Information

Address Romania
Luxembourg, L-1246
Luxembourg
Phone +352 46 66 67 212

Top Executives

Name Title Since Until
Akiva Felt - 2020 Now
Biography Mr. Felt has been a portfolio manager, providing research and advice on the purchases and sales of individual securities and portfolio risk assessment. He joined Franklin Templeton in 2018. Prior to joining Franklin Templeton, Mr. Felt was a Senior Research Analyst with Asymmetry Capital, a healthcare focused hedge fund. He has covered the biotechnology sector since 2007 in increasing capacities on the sell-side, most recently as Managing Director for Oppenheimer & Co.
Wendy Lam Portfolio Manager 2018 Now
Biography Ms. Lam has joined Franklin Templeton Investments in 2016. Prior to joining Franklin Templeton, Ms. Lam was an Executive Director and Senior Analyst covering large-cap biotechnology for Oppenheimer & Co and had been an Equity Research Associate at Bank of America Merrill Lynch, Morgan Stanley and Oppenheimer & Co. Ms. Lam has a Ph.D degree.
Evan S. McCulloch Vice President 2000 Now
Biography Mr. McCulloch, CFA, joined Franklin Templeton Investments in 1992.
Steven Kornfeld Portfolio Manager 2015 2020
Biography Steven Kornfeld is VP, Research Analyst and Portfolio Manager with Franklin Equity Group. He specializes in research analysis of the pharmaceutical industry and is a member of the Franklin Core/Hybrid team. Prior to joining Franklin Templeton Investments in January 2001, Mr. Kornfeld most recently worked in private equity and previously as a sell-side research analyst where he specialized in covering emerging growth companies. He holds an MBA from Northwestern University and a bachelor’s degree from the Wharton School of Business at the University of Pennsylvania. He is a CFA®* Charterholder.
Jerel A. Banks senior equity research analyst 2012 2015
Biography JEREL A. Banks has been a portfolio manager of the Fund since September 2012, providing research and advice on the purchases and sales of individual securities and portfolio risk assessment. He joined Franklin Templeton Investments in 2012. Prior to joining Franklin Templeton Investments, he was a senior equity research analyst at Sectoral Asset Management and Apothecary Capital and an equity research associate at Capital Research and Management.
Vincent Xiang Manager 2004 2011
Biography Xiang is a manager of the fund providing research and advice on the purchases and sales of individual securities and portfolio risk assessment. He joined Franklin Templeton Investments in 2004. Previously, Xiang was a vice president of business development at Genyous Life Sciences, Inc. He also worked on deal sourcing, due diligence and strategic planning at BioAdvance and as a senior analyst for Acacia Research Corporation.
Kurt von Emster Portfolio Manager 2000 2000
Biography Von Emster is currently a portfolio manager with Franklin Advisers. He joined the firm in 1989 as a management trainee and securities analyst. Previously, he was a purchasing agent for the University of California at Santa Barbara's Marine Science Institute. Von Emster is a Chartered Financial Analyst and a member of the Security Analysts of San Francisco.
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

0P00000MJJ Comments

Write your thoughts about Franklin Biotechnology Discovery Fund N(acc)usd
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Apple
Continue with Google
or
Sign up with Email